<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460924</url>
  </required_header>
  <id_info>
    <org_study_id>ARTiBIOME: Observational study</org_study_id>
    <nct_id>NCT04460924</nct_id>
  </id_info>
  <brief_title>ARTiBIOME: Observational Study on the Effect of HIV and ART on Gut Microbiome</brief_title>
  <official_title>ARTiBIOME: Effect of HIV and ART on Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiretroviral treatment for HIV has allowed patients to have undetectable viral load&#xD;
      indefinitely. Despite that, HIV infection has become a chronic inflammatory disease, with&#xD;
      increased mortality. This pro-inflammatory state is in part explained by the dysbiosis of&#xD;
      intestinal bacterial populations. However, little is known on the impact of the&#xD;
      antiretroviral treatment on this population and very few studies have evaluated these&#xD;
      alterations.&#xD;
&#xD;
      The aim of this study is to study microbiome on healthy patients and HIV-infected patients&#xD;
      exposed to antiretroviral treatment with integrase strand transfer inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Alpha diversity changes of fecal microbiota composition</measure>
    <time_frame>Baseline and 1 month, 3 months, 12 months</time_frame>
    <description>Alpha diversity changes of fecal microbiota composition between study groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta diversity changes of fecal microbiota composition</measure>
    <time_frame>Baseline and 1 month, 3 months, 12 months</time_frame>
    <description>Beta diversity changes of fecal microbiota composition between study groups</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>MSM HIV-uninfected and ART naïve</arm_group_label>
    <description>Men who have sex with men without HIV infection, not receiving ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSM HIV-infected starting ART</arm_group_label>
    <description>Men who have sex with men with HIV infection, starting ART</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSM HIV-infected on ART with &gt;500 CD4 Tcells</arm_group_label>
    <description>Men who have sex with men with HIV infection, on ART and with &gt;500 CD4 T cells/uL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSM HIV-infected on ART with &lt;350 CD4 Tcells</arm_group_label>
    <description>Men who have sex with men with HIV infection, on ART and with &lt;350 CD4 T cells/uL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MSM HIV negative patients starting PEP with INST</arm_group_label>
    <description>Men who have sex with men without HIV infection, starting post-exposure prophylaxis with raltegravir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Integrase strand transfer inhibitors</intervention_name>
    <description>Integrase strand transfer inhibitors as post-exposure prophylaxis or as antiretroviral treatment</description>
    <arm_group_label>MSM HIV negative patients starting PEP with INST</arm_group_label>
    <arm_group_label>MSM HIV-infected on ART with &lt;350 CD4 Tcells</arm_group_label>
    <arm_group_label>MSM HIV-infected on ART with &gt;500 CD4 Tcells</arm_group_label>
    <arm_group_label>MSM HIV-infected starting ART</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Feces&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will compare 20 MSM HIV negative patients starting PEP with INSTI with:&#xD;
&#xD;
          -  20 MSM HIV-uninfected and ART naïve (A)&#xD;
&#xD;
          -  20 MSM HIV-infected starting ART (B)&#xD;
&#xD;
          -  20 MSM HIV-infected on ART with &gt;500 CD4 Tcells ( C )&#xD;
&#xD;
          -  20 MSM HIV-infected on ART with &lt;350 CD4 Tcells (D) (the study population has been&#xD;
             restricted to MSM given the strong influence of sexual orientation on the microbiota&#xD;
             composition&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Willing to sign consent form&#xD;
&#xD;
          -  Men with an age &gt;18 years&#xD;
&#xD;
          -  Engagement in insertive or receptive anal intercourse with another men&#xD;
&#xD;
             *Exclusion criteria:&#xD;
&#xD;
          -  Previous history of ART exposure&#xD;
&#xD;
          -  Use of antibiotics in the past 3 months&#xD;
&#xD;
          -  Previous history of inflammatory bowel disease, autoimmune disease or cirrhosis.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal and Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Serrano-Villar, MD, PhD</last_name>
      <phone>0034913368711</phone>
      <email>serranovillar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sergio Serrano-Villar, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 26, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Integrase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

